Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL.
Anand P, Guillaumet-Adkins A, Dimitrova V, Yun H, Drier Y, Sotudeh N, Rogers A, Ouseph MM, Nair M, Potdar S, Isenhart R, Kloeber JA, Vijaykumar T, Niu L, Vincent T, Guo G, Frede J, Harris MH, Place AE, Silverman LB, Teachey DT, Lane AA, DeAngelo DJ, Aster JC, Bernstein BE, Lohr JG, Knoechel B. Anand P, et al. Among authors: vijaykumar t. Blood. 2021 May 6;137(18):2463-2480. doi: 10.1182/blood.2019004547. Blood. 2021. PMID: 33227818 Free PMC article.
Tracking myeloma tumor DNA in peripheral blood.
Waldschmidt JM, Vijaykumar T, Knoechel B, Lohr JG. Waldschmidt JM, et al. Among authors: vijaykumar t. Best Pract Res Clin Haematol. 2020 Mar;33(1):101146. doi: 10.1016/j.beha.2020.101146. Epub 2020 Jan 14. Best Pract Res Clin Haematol. 2020. PMID: 32139012 Free PMC article. Review.
Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma.
Waldschmidt JM, Kloeber JA, Anand P, Frede J, Kokkalis A, Dimitrova V, Potdar S, Nair MS, Vijaykumar T, Im NG, Guillaumet-Adkins A, Chopra N, Stuart H, Budano L, Sotudeh N, Guo G, Grassberger C, Yee AJ, Laubach JP, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG. Waldschmidt JM, et al. Among authors: vijaykumar t. Clin Cancer Res. 2021 Dec 1;27(23):6432-6444. doi: 10.1158/1078-0432.CCR-21-2040. Epub 2021 Sep 13. Clin Cancer Res. 2021. PMID: 34518309 Free PMC article.
Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma.
Frede J, Anand P, Sotudeh N, Pinto RA, Nair MS, Stuart H, Yee AJ, Vijaykumar T, Waldschmidt JM, Potdar S, Kloeber JA, Kokkalis A, Dimitrova V, Mann M, Laubach JP, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG. Frede J, et al. Among authors: vijaykumar t. Nat Cell Biol. 2021 Nov;23(11):1199-1211. doi: 10.1038/s41556-021-00766-y. Epub 2021 Oct 21. Nat Cell Biol. 2021. PMID: 34675390 Free PMC article.
Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma.
Waldschmidt JM, Yee AJ, Vijaykumar T, Pinto RA, Frede J, Anand P, Bianchi G, Guo G, Potdar S, Seifer C, Nair MS, Kokkalis A, Kloeber JA, Shapiro S, Budano L, Mann M, Friedman R, Lipe B, Campagnaro E, O'Donnell EK, Zhang CZ, Laubach JP, Munshi NC, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG. Waldschmidt JM, et al. Among authors: vijaykumar t. Leukemia. 2022 Apr;36(4):1078-1087. doi: 10.1038/s41375-021-01492-y. Epub 2022 Jan 13. Leukemia. 2022. PMID: 35027656 Free PMC article. Clinical Trial.
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing.
Guo G, Raje NS, Seifer C, Kloeber J, Isenhart R, Ha G, Yee AJ, O'Donnell EK, Tai YT, Richardson PG, Bianchi G, Laubach JP, Warren D, Gemme E, Voisine J, Frede J, Kokkalis A, Yun H, Dimitrova V, Vijaykumar T, Meyerson M, Munshi NC, Anderson KC, Knoechel B, Lohr JG. Guo G, et al. Among authors: vijaykumar t. Leukemia. 2018 Aug;32(8):1838-1841. doi: 10.1038/s41375-018-0115-z. Epub 2018 Mar 27. Leukemia. 2018. PMID: 29749395 Free PMC article. Clinical Trial. No abstract available.
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering.
Li L, Mohanty V, Dou J, Huang Y, Banerjee PP, Miao Q, Lohr JG, Vijaykumar T, Frede J, Knoechel B, Muniz-Feliciano L, Laskowski TJ, Liang S, Moyes JS, Nandivada V, Basar R, Kaplan M, Daher M, Liu E, Li Y, Acharya S, Lin P, Shanley M, Rafei H, Marin D, Mielke S, Champlin RE, Shpall EJ, Chen K, Rezvani K. Li L, et al. Among authors: vijaykumar t. Sci Adv. 2023 Jul 28;9(30):eadd6997. doi: 10.1126/sciadv.add6997. Epub 2023 Jul 26. Sci Adv. 2023. PMID: 37494448 Free PMC article.
A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma.
Hanna GJ, ONeill A, Cutler JM, Flynn M, Vijaykumar T, Clark JR, Wirth LJ, Lorch JH, Park JC, Mito JK, Lohr JG, Kaufman J, Burr NS, Zon LI, Haddad RI. Hanna GJ, et al. Among authors: vijaykumar t. Oral Oncol. 2021 Aug;119:105366. doi: 10.1016/j.oraloncology.2021.105366. Epub 2021 Jun 3. Oral Oncol. 2021. PMID: 34091189 Clinical Trial.
22 results